🔴 Femasys is trading 7.75% down in pre-market after profit-taking following FDA’s modular PMA pathway approval

Femasys is trading at $2.50 (-7.75%) in pre-market on August 20, 2026, with weakness appearing to reflect profit-taking after FDA approval of a modular PMA pathway for FemBloc.

• Shares rallied sharply on August 19 following the regulatory milestone, then surrendered most gains.
• The pathway allows staged regulatory review but does not approve U.S. marketing.